Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...